Cencora, Inc. · NYSE:COR
Cencora — AmerisourceBergen — Q3 FY2022 Earnings Presentation
17 slides from Cencora's earnings presentation, Aug 3, 2022
Slide 1: Q3 FY2022 Financial Results
Q3 FY2022 Financial Results August 3, 2022
Slide 2: Cautionary note regarding forward-looking statements
Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securit
Slide 3: AmerisourceBergen is united in our responsibility to create healthier futures
AmerisourceBergen is united in our responsibility to create healthier futures. AmerisourceBergen creates unparalleled access, efficiency, and reliability for human and animal health as a leading provider of pharmaceutical distribution services and differentiated value-added solutions for upstream an
Slide 4: Overview
Overview Recent highlights Global healthcare Fiscal 2022 guidance leader • Growth driven by strong • Foundation of leadership • Increased guidance reflects execution and strength in pharmaceutical stronger than expected and resilience of distribution performance of several business • Complementary h
Slide 5: Q3 FY2022 financial results
Q3 FY2022 financial results Consolidated results GAAP Adjusted (non-GAAP)1 Revenue $60.1B $60.1B % Change (Year-over-Year) 12.5% 12.5% Gross profit $2.0B $2.1B % Change 6.7% 27.0% Operating expenses $1.5B $1.3B % Change 20.6% 31.5% Operating income $487M $756M % Change (21.5%) 19.9% Interest expense
Slide 6: Q3 FY2022 financial results: U.S. Healthcare Solutions segment
Q3 FY2022 financial results U.S. Healthcare Solutions segment Q3 FY2022 Q3 FY2021 YoY Change Revenue $53.4B $50.4B 6.0% Operating income $580M $530M 9.5% Percentages of revenue Gross profit 2.49% 2.44% Operating expenses 1.40% 1.38% Operating income 1.09% 1.05% ▪ U.S. Healthcare Solutions consists o
Slide 7: Q3 FY2022 financial results: International Healthcare Solutions segment
Q3 FY2022 financial results International Healthcare Solutions segment Q3 FY2022 Q3 FY2021 YoY Change Revenue, as reported $6.7B $3.0B 120.3% Revenue, constant currency1 $7.7B 155% Operating income, as reported $176M $101M 74.8% Operating Income, constant currency 1 $214M 112% Percentages of revenue
Slide 8: FY2022 guidance
FY2022 guidance Updated guidance reflects stronger than expected performance in several businesses and lower average diluted share count Revenue High-single to low-double digit percent growth U.S. Healthcare Solutions revenue $207 billion to $212 billion represents growth of 2% to 5% International H
Slide 9: Creating differentiated value for our stakeholders
Creating differentiated value for our stakeholders Our long-term, sustainable growth is supported by investments in our people and culture and commitment to ESG Why we exist Our 5 Strategic Imperatives We are united in our responsibility to create healthier futures Advance core business Enhance capa
Slide 10: Advancing environmental, social, and governance initiatives to create healthier futures
Advancing environmental, social, and governance initiatives to create healthier futures around the world ENVIRONMENTAL SOCIAL Adapting to a changing climate Investing in our people and communities • Reduced greenhouse gas emissions by 4.6% • Long-term diversity, equity, and inclusion in fiscal 2021
Slide 11: Appendix
Appendix
Slide 12: Note: For more information related to non-GAAP financial measures, refer to the section titled
1. Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss, Net. 12 Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Informa
Slide 13: Note: For more information related to non-GAAP financial measures, refer to the section titled
1. Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million of income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss, Net. 2. The sum of the components does not
Slide 14: Supplemental Information Regarding Non-GAAP Financial Measures
Supplemental Information Regarding Non-GAAP Financial Measures To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses the non-GAAP financial measures described below. The non-GAAP financial measures should be viewed in
Slide 15: Supplemental Information Regarding Non-GAAP Financial Measures (Cont.)
Supplemental Information Regarding Non-GAAP Financial Measures (Cont.) • Adjusted income before income taxes: Adjusted income before income taxes is a non-GAAP financial measure that excludes the same items that are described above and excluded from adjusted operating income. In addition, the gain (
Slide 16: Supplemental Information Regarding Non-GAAP Financial Measures (Cont.)
Supplemental Information Regarding Non-GAAP Financial Measures (Cont.) • Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments including gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credi
Slide 17: Contact
Contact Bennett S. Murphy Senior Vice President Investor Relations bmurphy@amerisourcebergen.com